Daniel A. Vallera mainly focuses on Immunology, Graft-versus-host disease, T cell, Bone marrow and Cytotoxic T cell. His Immunology study integrates concerns from other disciplines, such as Haematopoiesis and Transplantation. His studies deal with areas such as T lymphocyte, Interleukin 2, Cytokine, Spleen and Antibody as well as Graft-versus-host disease.
His T cell research is multidisciplinary, incorporating perspectives in Ex vivo, Cancer research, CD40, Immunotoxin and Clonogenic assay. His work carried out in the field of Bone marrow brings together such families of science as Progenitor cell, Total body irradiation, Cyclophosphamide, Leukemia and Acute lymphocytic leukemia. His work in Cytotoxic T cell addresses subjects such as Antigen, which are connected to disciplines such as Molecular biology.
Daniel A. Vallera mainly investigates Immunology, Cancer research, Immunotoxin, Bone marrow and Molecular biology. His study in Immunology is interdisciplinary in nature, drawing from both Cytotoxic T cell and Graft-versus-host disease, Transplantation. His Cytotoxic T cell research incorporates elements of CD8 and Antigen.
His Cancer research research also works with subjects such as
His primary areas of investigation include Cancer research, Myeloid leukemia, Antibody, Immunology and Immunotherapy. His Cancer research research incorporates themes from Cancer, Urokinase receptor, Leukemia, CD33 and Interleukin 15. He usually deals with CD33 and limits it to topics linked to Bone marrow and Monoclonal antibody, Total body irradiation, Multiple myeloma, Whole body imaging and Humanized antibody.
His Antibody research is multidisciplinary, relying on both Priming, Antigen and Diphtheria toxin. His Diphtheria toxin study deals with Fusion protein intersecting with Immune system. His Stem cell study integrates concerns from other disciplines, such as T cell and Lymphocyte.
His primary scientific interests are in Cancer research, Immune system, Immunology, Immunotoxin and Receptor. The concepts of his Cancer research study are interwoven with issues in Urokinase receptor, Cancer, Sarcoma and Interleukin 15. His Immune system research integrates issues from Antibody and Stem cell.
His Immunotherapy, Interleukin 21 and Lymphokine-activated killer cell investigations are all subjects of Immunology research. His research integrates issues of T cell, Adoptive cell transfer, Hematopoietic stem cell transplantation and Lymphocyte in his study of Immunotherapy. Many of his studies on Immunotoxin apply to Immunogenicity as well.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.
John H. Kersey;Daniel Weisdorf;Mark E. Nesbit;Tucker W. LeBien.
The New England Journal of Medicine (1987)
In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
Bruce R Blazar;Patricia A. Taylor;Peter S. Linsley;Daniel A Vallera.
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
William J Murphy;Lisbeth A. Welniak;Dennis D. Taub;Robert H. Wiltrout.
Journal of Clinical Investigation (1998)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Qing Zhou;Meghan E. Munger;Steven L. Highfill;Jakub Tolar.
Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease.
A.H Filipovich;A.H Filipovich;R.J Youle;R.J Youle;D.M Neville;D.M Neville;D.A Vallera;D.A Vallera.
The Lancet (1984)
Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Bruce R Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Janet Buhlman.
Journal of Immunology (1997)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason;Michael R. Verneris;Deborah A. Todhunter;Bin Zhang.
Molecular Cancer Therapeutics (2012)
Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice
Angela Panoskaltsis-Mortari;Angela Panoskaltsis-Mortari;David L. Lacey;David L. Lacey;Daniel A. Vallera;Daniel A. Vallera;Bruce R. Blazar;Bruce R. Blazar.
Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
Bruce R. Blazar;Patricia A. Taylor;Sidney Smith;Daniel A. Vallera.
Recent advances in graft-versus-host disease (GVHD) prevention
Bruce R Blazar;Robert Korngold;Daniel A Vallera.
Immunological Reviews (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: